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Gastrointestinal cancers, including oesophageal, gastric and colorectal cancers (CRC)
have high rates of disease recurrence despite curative resection. There are a number
of recent studies that have investigated the use of circulating tumor DNA (ctDNA)
for prognostic value in these cancers. We reviewed studies that had been published
prior to March 2018 that assessed the prognostic values of ctDNA in patients with
oesophageal and gastric cancers, gastrointestinal stromal tumors (GIST) and CRC. We
identified 63 eligible clinical studies that focussed on recurrence and survival. Studies
assessed investigated various ctDNA biomarkers in patients with different stages of
cancer undergoing surgical resection, chemotherapy and no treatment. For oesophageal
squamous cell carcinoma and oesophageal adenocarcinoma, methylation of certain
genes such as APC and DAPK have been highlighted as promising biomarkers for
prognostication, but these studies are limited and more comprehensive research is
needed. Studies focusing on gastric cancer patients showed that methylation of ctDNA
in SOX17 and APC were independently associated with poor survival. Two studies
demonstrated an association between ctDNA and recurrence and survival in GIST
patients, but more studies are needed for this type of gastrointestinal cancer. A large
proportion of the literature was on CRC which identified both somatic mutations and
DNA methylation biomarkers to determine prognosis. ctDNA biomarkers that identified
somatic mutations were more effective if they were personalized based on mutations
found in the primary tumor tissue, but ctDNA methylation studies identified various
biomarkers that predicted increased risk of recurrence, poor disease free survival
and overall survival. While the use of non-invasive ctDNA biomarkers for prognosis is
promising, larger studies are needed to validate the clinical utility for optimizing treatment
and surveillance strategies to reduce mortality from gastrointestinal cancers.
Keywords: circulating tumor DNA, colorectal cancer, oesophageal cancer, gastric cancer, gastrointestinal stromal
tumor, cell free circulating DNA, survival, recurrence
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INTRODUCTION
Gastrointestinal cancers, in particular gastric (stomach) and
colorectal cancer (CRC), have high incidence and mortality
rate. CRC is one of the most prevalent cancers, with ∼1.4
million new cases diagnosed and 693,933 deaths worldwide
per year in 2012 (1). The incidence and mortality rate of
gastric cancer during the same period was 951,594 and 723,073
respectively, while oesophageal (adenocarcinoma or squamous
cell carcinoma) cancer incidence was 455,784 with a mortality
of 400,169. From this it can be seen that while the incidence of
oesophageal cancer is less common than gastric cancer and CRC,
it has a higher mortality rate which is due to the tumors being
rarely detected before the disease has metastasized to lymph
nodes and distant organs (2, 3). Gastrointestinal stromal tumors
(GIST) are mesenchymal tumors that can originate anywhere in
the gastrointestinal tract, but with a higher proportion in the
stomach and small intestine. They are not common and are
thought to make up <1% of all gastrointestinal tumors. Five year
survival from this cancer is∼50% (2, 4).
In recent years there have been large improvements in early
detection, surgical resection and treatment of gastrointestinal
cancers, especially colorectal and gastric. Despite this, the risk of
recurrence of the cancer within 5 years is reported to be up to
50% (4–6). For oesophageal cancer and GIST approximately half
of the patients undergoing curative resection develop recurrence
(4, 5), with half of the oesophageal recurrences occurring within
the first year post-resection (5). Despite deeming patients free
of disease at the conclusion of initial therapy, gastric cancer has
been reported to have a recurrence incidence of 26% (7), and
following CRC resection, incidence of recurrence is ∼35%, with
80% occurring within the first 2 years of resection (6). Metastatic
recurrence is most commonly detected too late for successful
intervention (8, 9) although for CRC at least early detection
of tumor progression and recurrence provides an additional
effective way to improve clinical outcomes. Accurate prognostic
assessment to allow for early and effective treatment is vital to
improving patient outcomes.
CURRENT TOOLS FOR PROGNOSIS AND
SURVEILLANCE
Assessment of prognosis and determining treatment and
surveillance strategies is currently guided by the stage at diagnosis
which is classified according to the T, N, M system, i.e., depth of
tumor invasion (T stage), presence of lymph node metastasis (N
stage), and presence of distancemetastasis (M stage) (10). Staging
of GIST is based on tumor size instead of depth of invasion, with
mitotic rate combined with T, N, and M scores to give an overall
stage (11). While the use of TNM stage is highly prognostic
for stage I and IV, it is less predictive for stage II and III. For
example, patients with stage II CRC are considered to have low
risk for recurrence and therefore are not generally recommended
adjuvant chemotherapy, but despite this, one study found that
23% of stage II patients had a recurrence within 5 years (12).
Consequently, other clinicopathological factors have been sought
to help predict who is at greatest risk for recurrence (examples
provided in Table 1). For oesophageal cancer increased depth
of tumor invasion correlates with an increased risk of disease
recurrence (14), however it is not highly predictive of which
patients are at low or high risk for disease recurrence. Similarly
for CRC, T stage, vascular invasion, tumor grade, and number of
examined lymph nodes have been associated with poor prognosis
(Table 1), however, recurrence still occurs in patients without
these risk factors (31).
Intensive surveillance after resection may be applied to detect
asymptomatic recurrence early enough to enable curative therapy
and improve survival. Current methods for surveillance post-
resection are radiological techniques (e.g., CT) and endoscopy
with biopsy, but these have disadvantages of radiation burden,
lack of sensitivity, invasive nature, and cost as well as limited
resources in some countries. Biopsy only samples a small area
of the epithelium which might not be representative of the stage
of disease (3). In addition the cost effectiveness of intensive
surveillance has been questioned (32). Oesophageal cancers may
also benefit from surveillance with cytological sampling obtained
by brushing the oesophageal surface, or use of the capsule sponge,
but these techniques are also limited by inadequate sensitivity and
specificity, or limited validation (3). There remains a need for
non-invasive and sensitive prognostic markers to establish who
would benefit from adjuvant therapy and surveillance. This could
be done through pre- or post-operative blood analysis.
ASSESSMENT OF BLOOD FOR
BIOMARKERS OF CANCER PROGNOSIS
The use of blood biomarkers has the potential to provide further
prognostic information of value for gastrointestinal cancers,
however, current clinical use is limited. Blood testing for proteins
are not routinely used for oesophageal cancers or GIST, but
the proteins carcinoembryonic antigen (CEA), carbohydrate
antigen-19-9 (CA 19-9), and carbohydrate antigen 72-4 (CA 72-
4) have been used for monitoring disease progression of CRC
and gastric cancer (33). For CEA, while it is upregulated in 90%
of advanced CRC (34), it is not reliably used for prognosis, and
studies have shown an unacceptably low sensitivity for recurrent
CRC of 32–37% (35–37). The sensitivity of CEA for recurrence
in gastric cancer has been reported to be between 30.8 and 34.3%
(38, 39). There is a wide range of sensitivity of CA 19-9 of 30.8–
57.1% (38, 39), with a similar average sensitivity of CA 72-4 of
48.4% (39). The low sensitivity supports the need for other blood
biomarkers for clinical management to assess risk for recurrence.
Genetic markers arising from tumors and being released into
blood might provide the solution. Most gastrointestinal cancers
are thought to develop through a series of epigenetic changes
or somatic (non-hereditary) lesions. The common mutations are
in genes including APC, TP53, KRAS and BRAF for colorectal
cancer [reviewed in Testa et al. (40)], TP53 and p16/CDKN2A
in oesophageal adenocarcinomas [reviewed in Testa et al. (41)],
CDH1, PIK3CA, and RHOA in gastric cancers [reviewed in
Ang et al. (42)], and KIT and PDGFRA with GIST [reviewed
in Wozniak et al. (43)]. These alterations can contribute to
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TABLE 1 | Significant predictive clinicopathological factors of recurrence for gastrointestinal cancers on multivariate analysis.
Patient group Clinicopathological variable Multivariate analysis findings
Oesophageal cancers (73.3% adenocarcinomas) (13) Poor differentiation HR 1.74; 95%CI 1.28–2.38
Advanced clinical stage HR 6.46; 95%CI 2.90–14.38
Oesophageal cancers (82.5% squamous cell carcinoma) (14) Depth of tumor invasion RR 1.9; 95%CI 1.3–2.7
Gastric cancer (15) Age at diagnosis OR 1.813; 95%CI 1.050–3.131
T stage OR 2.865; 95%CI 1.603–5.123
N1 stage (vs. N0) OR 4.029; 95%CI 1.708–9.500
N2 stage (vs. N0) OR 4.425; 95%CI 1.889–10.365
N3 stage (vs. N0) OR 9.860; 95%CI 4.314–22.536
Lauren histotype OR 3.492; 95%CI 1.810–6.736
Lymphovascular invasion OR 3.460; 95%CI 1.335–8.969
Gastric cancer (lymph node negative) (16) T stage ≥3 SHR 2.7; 95%CI 1.5–5.2
Gastric cancer (lymph node negative) (17) Diffuse + mixed histotype (vs.
intestinal)
RR 2.11; 95%CI 1.25–2.95
T3 stage (vs. T2) RR 3.55; 95%CI 1.98–6.44
Gastrointestinal stromal tumor (18) Mitotic index 6-10/50 HPF (vs. ≤5/50) RR 0.282; 95%CI 0.121–0.660
Platelet to lymphocyte ratio RR 1.737; 95%CI 1.041–2.899
Gastrointestinal bleeding RR 0.457; 95%CI 0.254–0.823
Gastrointestinal stromal tumor (19) High risk HR 13.01; 95%CI 2.68–63.21
Omental/colorectal site HR 5.13; 95%CI 1.68–15.69
Age at diagnosis HR 0.96; 95%CI 0.92–0.99
Gastrointestinal stromal tumor (20) Size ≥5 cm (vs. <5 cm) HR 3.43; 95%CI 1.12–11.8
Mitotic index ≥5 (vs. <5/50 HPF) HR 3.28; 95%CI 1.25–8.59
Gastrointestinal stromal tumor (21) Female HR 0.469; 95%CI 0.257–0.854
Size ≥10 cm (vs. <5 cm) HR 20.989; 95%CI 3.560–125.673
Epithelioid component HR 5.315; 95%CI 1.402–20.149
Mitotic index ≥10 (vs. <10) HR 45.951; 95%CI 8.811–239.657
Gastrointestinal stromal tumor (22) Size ≥10 cm (vs. <10 cm) OR 4.715; 95%CI 1.142–19.471
Colon cancer (stage I-III) (23) Stage II (vs. I) HR 4.6; 95%CI 1.05–19.9
Stage III (vs. I) HR 10.8; 95%CI 2.6–45.8
Clinical obstruction HR 3.8; 95%CI 1.9–7.4
Positive margin HR 4.1; 95%CI 1.9–8.6
Lymphovascular invasion HR 1.9; 95%CI 1.06–3.5
Local tumor invasion HR 2.2; 95%CI 1.1–4.5
Colon cancer (stage III) (24) Positive lymph node HR 1.24; 95%CI 1.18–1.31
Colon cancer (stage I-III) (25) 4.0–7.9 cm (vs. <4 cm) HR 0.45; 95%CI 0.293–0.696
Venous invasion HR 1.61; 95%CI 1.085–2.376
Stage III (vs. stage I) HR 3.80; 95%CI 1.482–9.744
Rectal cancer (stage I-III) (25) Lower rectum (vs. rectosigmoid) HR 2.20; 95%CI 1.408–3.424
Anal canal (vs. rectosigmoid) HR 7.19; 95%CI 3.052–16.950
Serosal invasion HR 1.63; 95%CI 1.130–2.343
Venous invasion HR 1.90; 95%CI 1.407–2.566
Stage III (vs. stage I) HR 3.64; 95%CI 1.993–6.634
Questionable residual tumor HR 1.84; 95%CI 1.281–2.634
Rectal cancer (stage III) (26) tumor budding HR 2.005; 95%CI 1.021–3.934
N stage HR 1.818; 95%CI 1.057–3.128
Perineural invasion HR 1.046; 95%CI 1.011–1.081
T stage HR 1.606; 95%CI 1.149–2.244
Colorectal cancer (stage I-III) (27) Vascular invasion HR 2.304; 95%CI 1.067–4.975
Perineural invasion HR 3.040; 95%CI 1.389–6.667
Colorectal cancer (stage I-III) (28) Lymph node metastases HR 7.652; 95%CI 4.162–14.827
(Continued)
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TABLE 1 | Continued
Clinicopathological variable Multivariate analysis findings
Vascular invasion HR 4.360; 95%CI 2.793–10.847
Colorectal cancer (stage II) (29) T4 stage (vs. T3) HR 23.072; 95%CI 2.951–203.247
Vascular invasion HR 6.204; 95%CI 2.879–12.694
≥12 lymph nodes retrieved HR 2.656; 95%CI 1.319–6.127
Colorectal cancer (stage IV) (30) High grade differentiation HR 1.514; 95%CI 1.124–2.040
Curative operation HR 2.642; 95%CI 1.966–3.549
Resection of primary tumor HR 0.507; 95%CI 0.366–0.704
Multiple metastatic lesions HR 1.679; 95%CI 1.165–2.418
95% CI, confidence interval; HR, hazard ratio; OR, odds ratio; SHR, subhazard ratio.
aberrant cell behavior such as uncontrolled cell growth and
proliferation, disordered apoptosis, increased angiogenesis, and
promotion of invasion and metastasis (44). As primary and
metastatic cancers shed cells, cell components and DNA into
the blood, these genetic changes can be monitored in the
circulation by assaying for circulating tumor cells (CTCs) or for
circulating tumor DNA (ctDNA), with the process sometimes
referred to as liquid biopsy. While CTCs show promise in early
detection of recurrence [reviewed in Tan et al. (45)], clinical
use is limited by low numbers of CTCs in the blood (one mL
of whole blood generally contains less than one CTC, but 107
normal blood cells) (46). Furthermore, CTCs show heterogeneity
such that extraction techniques might not be effective for all
cell types; CTCs can be comprised of epithelial tumor cells,
epithelial-to-mesenchymal transition (EMT) cells, and stem cells
(46). The use of ctDNA which is more abundant and easier
to extract, overcomes some of the technical issues associated
with using CTCs in clinical practice and captures the genetic
material released independent of cell structure. ctDNA remains
in the circulation for a few hours before being metabolized, (47)
which allows real-time monitoring of the tumor burden, with
a comprehensive molecular profile of the heterogeneity of the
disease, compared to what is provided by a single tumor tissue
biopsy (48).
The release of ctDNA into the bloodstream as cell free DNA
(cfDNA) is thought to be the result of apoptosis or necrosis
of tumor cells (49). When DNA is released through necrosis
of cells, the fragments can vary in size, whereas DNA released
through apoptosis creates fragments 185–200 base pairs in length
(50). As the main source of DNA from non-neoplastic healthy
cells is apoptosis, assessment of the ratio of longer DNA to
short fragments (through measuring ALU repeats) is able to
indicate presence of ctDNA (51). Other common strategies
involve assessing cell free DNA levels, tumor specific DNA
mutations, and tumor specific epigenetic changes. The latter
two can be assessed through targeted PCR-based ctDNA assays,
detecting known somatic mutations or epigenetic changes. One
such example is assessment of RAS mutations of colorectal
cancer tissue which are of similar prevalence in plasma as in
the tumor (51 and 53% respectively), demonstrating that blood-
based testing for RAS mutation is a viable alternative to tissue-
based testing (52). A growing number of studies have assessed
DNA methylation as there is evidence that epigenetic alterations
are more common and frequently precede mutational (somatic)
changes (53). Also unlike mutations, promoter methylation can
be consistently measured as it occurs in specific regions of the
DNA (CpG islands).
CtDNA has been evaluated as a screening tool and for
diagnostic purposes, but there has been limited effectiveness with
early stage cancers and it does not appear useful in predicting
the presence of colonic polyps (54). Instead the use of ctDNA
for prognosis and treatment monitoring is more promising. The
following sections of this review will describe the studies that
have been performed in gastrointestinal cancers to assess the
utility of ctDNA for their prognostic value, whether measured
as cfDNA concentration, integrity (fragment lengths), copy
number alterations, mutation or methylation status. These are
comprehensively summarized in Supplementary Tables 1–4.
SEARCH STRATEGY
Identification of eligible studies was performed through
searching the PubMed database until 1st March 2018. The
following search criteria were applied: “(ctDNA OR “circulating
tumor DNA” OR “tumor derived DNA” OR “circulating tumor
DNA” OR “tumor derived DNA” OR “cell free DNA”) AND
(gastrointestinal OR GIT OR esophagus OR esophagus OR
oesophageal OR esophageal OR gastroesophageal OR stomach
OR gastric OR “large intestine” OR colon OR caecum OR
rectum OR colorectal) AND (tumor OR tumor OR malignan∗
OR cancer OR neoplasm OR carcinoma OR carcinoid OR
adenocarcinoma).” This resulted in 657 search results. Two
independent reviewers (HS and ES) screened the available
literature, and discrepancies were discussed and resolved.
Included studies were those conducted in gastrointestinal
cancers with a clinical outcome of survival or recurrence.
Exclusions were review articles, biomarker studies that did not
include blood analysis, studies in animal models or cell lines
only, articles that were not in English, and those that analyzed
circulating tumor cells (CTC) rather than circulating tumor DNA
or cell free DNA. In the case of more than one report on the same
cohort of patients, the study with the shorter follow-up time was
excluded. In addition, studies were not included where the focus
was on associations of biomarkers with pathology indicators of
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poor prognosis, rather than an actual clinical outcome of poor
prognosis. The final number of eligible studies for review were
63, including 7 on oesophageal cancers, 13 on gastric cancers, 2
on GIST, and 41 on CRC.
CTDNA BIOMARKERS FOR PROGNOSIS
OF OESOPHAGEAL CANCER
Biomarkers for prognosis have been investigated for both
adenocarcinomas and squamous cell carcinomas of the
esophagus as summarized below.
DNA Levels, Integrity, and Copy Numbers
It was previously shown that cfDNA levels correlated with stage
in oesophageal squamous cell carcinoma (SCC). Tomochika et al
(n = 91) found that DNA levels were higher in advanced tumors
vs. early stages, and significantly higher in patients with distant
metastases (p = 0.011) (55). Correlation of DNA levels before
oesophagectomy for stage I-III SCC were also observed with
tumor lymphovascular invasion and relapse (p = 0.018), and
a poor 5 year disease free survival rate in 81 oesophageal SCC
patients (p= 0.013) (56).
DNA Mutations
Ueda et al conducted a longitudinal study to look at 53
cancer related genes in 13 oesophageal SCC patients undergoing
surgery of all stages. Changes in allele frequency in ctDNA was
associated with tumor burden, and the allelic frequency increased
prior to radiographic detection of recurrence (6 months before
radiological evidence) (57). Eisenberger et al assessed loss of
heterozygosity (LOH) in pre-operative ctDNA of SCC (n = 28)
and oesophageal adenocarcinoma (n = 32) patients of all stages
in two separate studies. In both types of cancers, no relationship
was found between recurrence and LOH; however, in SCC a trend
toward shorter survival was observed for patients with LOH in
tumor tissue and ctDNA (58, 59).
DNA Methylation
Of the few studies that have assessed prognostic value of
methylated ctDNA biomarkers in oespophageal cancer, there
have been mixed outcomes, which may be related to different
cancer types studied. Presence of high pre-operative methylated
ctDNA (MSH2) was predictive of lower disease free survival
for 209 SCC patients of all stages (60), while in all stages of
oesophageal adenocarcinomas pre-operative methylated ctDNA
(TAC1) was not associated with survival (n = 61) (61). Hoffman
et al assessedmethylation ofDAPK andAPC promoter in 24 SCC
and 35 adenocarcinoma patients of stage 0-III at pre- and post-
operative stages. Presence of pre-operative DAPK methylation
was associated with poorer survival (p = 0.01) and detection of
post-operative methylation of APC promoter was correlated with
residual tumor (p= 0.03) (62).
Summary
There have been a limited number of studies undertaken
to develop prognostic biomarkers with oesophageal SCC and
adenocarcinoma. Some of these studies are highlighted inTable 2
[limiting the studies displayed to those with at least 20 events of
interest (recurrence or death)], but there have been very limited
accuracy data for each test. Only a test utilizing copy numbers
was assessed for sensitivity for recurrence (61.2%), but specificity
was not assessed (56).
CTDNA BIOMARKERS FOR PROGNOSIS
OF GASTRIC CANCER
DNA Levels, Integrity and Copy Numbers
A number of studies have investigated the use of cfDNA levels
to determine the clinical outcome following surgical resection
of gastric cancer. Kim et al (n = 30) and Pu et al (n = 73)
provided data that supported that advanced gastric cancer (stage
III/IV) patients had higher levels of DNA compared with early
gastric cancer patients (p = 0.035) (63, 64). Pu et al conducted a
longitudinal study and found that DNA levels were elevated pre-
operatively and at 21 days post-operatively; but they declined 3
months post-surgery and then increased again if the patient had
tumor progression. However this study showed no significant
association of DNA levels with survival (64). A large study of
428 gastric cancer patients by Lan et al found that persistently
high DNA levels post-resection was an indicator of recurrence
(65). In a study that focussed on 277 stage IV cases it was found
that a high level of DNA with more mutations was present pre-
operatively (p < 0.0001) and these patients had an increased risk
of recurrence (p = 0.037) and lower overall survival (p = 0.039)
over the 5-year follow-up period (8). Several studies have also
assessed DNA copy numbers for prognostic purposes. A study
by Shoda et al examined 61 stage I and II surgical resection
patients and found thatHER2 toRPPH1 ratio of ctDNA increased
post-operatively with recurrence (66). In a separate study, this
research group looked at the value of EBV (Epstein–Barr virus)
DNA in 153 gastric cancer patients undergoing resection. In
the 21 (13.7%) patients with EBV-associated gastric carcinoma,
circulating EBV DNA levels reflected the clinical status of the
patient as it was absent after surgery in all 9 cases assessed, and
increased prior to clinical detection of recurrence in one patient
with longitudinal follow-up over 2 years (67). While plasma EBV
DNA may useful for monitoring clinical load in patients with
EBV-associated gastric carcinomas, no significant difference was
found between prognosis of recurrence-free survival of those
with high pre-operative EBV copy numbers compared to those
with low levels (67). Kinugasa et al (68) assessed the ctDNA
HER2 status in relation to survival of patients with non-resectable
gastric cancer (2 stage III and 23 stage IV). They reported that
patients with a positive pre-therapy HER2 ctDNA status had
significantly shorter survival than patients with a negative status
(p = 0.01). However, as a poor concordance was found between
tissue and serum HER2 status, only 3 of the 7 patients that
were ctDNA HER2 positive were also positive with tissue biopsy
and received directed therapy (trastuzumab). No difference in
survival was found when comparing survival rates of patients
with a positive or negative HER2 status of the tissue. Caution
must therefore be taken in interpreting the prognostic value of
HER2 ctDNA status.
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Very few studies have assessed DNA mutations for gastric
cancer prognosis. One of the studies was a longitudinal
study in 42 stage II gastric cancer patients undergoing
surgical resection which evaluated concentration of TP53
mutations. It was found that the change in ctDNA fraction
corresponded with disease status of the patients i.e. the
levels decreased post-operatively but increased in patients with
recurrence (69). However, the authors did not perform statistical
analyses on these results as there were only 3 cases with
recurrence.
DNA Methylation
A few papers have studied methylation of ctDNA in gastric
cancer and found a significantly worse clinical outcome in
patients who have aberrant methylation of various genes in
ctDNA. Pimson et al found 85 and 95% of 101 advanced
gastric cancer patients had PCDH10 and RASSF1A methylation
which was associated with a reduction in median survival
to ∼8 months (p < 0.001) (70). Balgkouranidou et al also
studied RASSF1A methylation, along with APC methylation,
in 73 operable gastric cancer patients of stage I-III and did
not find a significant correlation with RASSF1A promoter
methylation and clinical outcome; but showed that the group
with pre-operative APC promoter methylation had a higher
incidence of death (HR 4.6, p = 0.008). APC methylation
levels were also associated with high levels of the conventional
tumor biomarkers, CEA and CA19-9 (71). In a similar study,
Balgkouranidou et al found that methylation of SOX17 in pre-
operative ctDNA of 73 patients with operable gastric cancer
had decreased overall survival (p = 0.049) (72). Two studies
investigated different ctDNA biomarkers, MINT2 promoter and
TIMP-3 respectively, for disease-free progression and risk of
recurrence in the same population of 92 gastric cancer patients
of all stages undergoing surgical resection. Aberrant methylation
ofMINT2 promoter in pre-operative ctDNA was associated with
peritoneal dissemination and tumor progression (p < 0.0001);
and methylation of TIMP-3 was associated with poorer disease
free survival rates (p < 0.001) (73, 74). A study by Ling
et al assessed XAF1 methylation in pre-operative and post-
operative follow-up ctDNA of 202 gastric cancer patients of all
stages and showed that negative to positive methylation change
post-surgery was associated with a poorer disease-free survival
(p < 0.0001) (75).
Summary
As with oesophageal cancers, there have been few thorough
studies into ctDNA for prognosis of gastric cancer (Table 3) and
none have shown to be an independent predictor for recurrence.
Methylation changes appear to be the most promising with
methylated RASSF1A and SOX17 being independent predictors
of overall survival. Despite this, the sensitivity and positive
predictive value reported for some of these biomarkers
may not be sufficiently high enough to guide therapeutic
decisions.
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CTDNA BIOMARKERS FOR PROGNOSIS
OF GASTROINTESTINAL STROMAL
TUMORS
Two studies looked at the role of ctDNA in prognosis of
GIST. In 92 patients with recurrent GIST, Rawnaq et al found
an association between loss of heterozygosity in microsatellite
DNA and recurrence (p = 0.03), but no association with
overall survival (76). A study by Yoo et al on 30 patients with
tyrosine kinase inhibitor-refractory GIST found that a detection
of secondary kinase mutations (KIT exon 17) prior to treatment
was associated with lower overall survival (HR 2.7, 0.047) (77).
Summary
Only the study by Rawnaq et al. (76) had a moderate sample
size, and has been summarized in Table 4. There have been
no investigations into methylation markers of ctDNA, and
the existing studies have not found a biomarker that is an
independent predictor of either recurrence or survival. More
studies are clearly needed for this type of gastrointestinal cancer.
CTDNA BIOMARKERS FOR PROGNOSIS
OF COLORECTAL CANCER
DNA Levels, Integrity and Copy Numbers
As demonstrated with other gastrointestinal cancers, level of
cfDNA correlates with presence and stage of tumors. Metastatic
CRC was found to have highest cfDNA levels, with these
decreasing for all patients post resection (n = 205) (51).
Cassinotti et al and Frattini et al noted that DNA levels increased
prior to recurrence in all stages of CRC (n= 223, n= 70) (78, 79).
In two different studies of 38 primary CRC patients, Czeiger
and colleagues found that pre-operative DNA level was a better
indicator of prognosis than TNM staging for both disease-free
survival (HR 6.03) and overall survival (HR 3.53) for all cancer
stages. They also showed that DNA levels out-performed pre-
operative CEA results, whichwas not significantly associated with
disease-free survival (80, 81). Guadaljara et al found that a high
level of pre-operative cfDNA in all CRC stages was correlated
with presence of metastases at the time of the surgery or during
follow up, but was not associated with overall survival (n = 73)
(82). Schwarzenbach et al only assessed 55 stage IV CRC patients
and found that high DNA levels prior to surgical resection was
associated with a shorter survival period (83). Shorter overall
survival has also been found to be associated with high pre-
operative DNA levels measured as DNA fragments (ALU244 and
ALU83, which are thought to represent the amount of the DNA
released from non-apoptotic process and the total cfDNA) and
DNA copy numbers (measured with DNA binding protein CPP1;
n= 114, n= 45 respectively) (84, 85).
In metastatic CRC patients being treated with chemotherapy,
high levels of cfDNA correlated with a worse outcome for the
patient. Spindler et al (n= 100) found patients with high level of
DNA prior to second-line treatment with irinotecan had shorter
progression-free survival and overall survival (p < 0.0001) (86).
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chemorefractory metastatic CRC, and patients with high DNA
levels had an impaired overall survival, with each increase
in cfDNA quartile having an independent prognostic value
(p= 0.0006) (87). In 49 patients with therapy resistant metastatic
CRC being treated with gemcitabine and capecitabine, it was
shown that high DNA levels prior to therapy was associated with
lower overall survival (88). Schou et al assessed cfDNA levels
longitudinally in 123 patients with locally advanced rectal cancer
receiving chemotherapy and found that a high baseline level was
associated with a higher risk of local/distant recurrence and a
shorter time to recurrence (p= 0.002) (89).
DNA Mutations
The relationship between pre-operative ctDNA and survival or
recurrence, using mutation markers, in CRC patients of all stages
has been explored in a number of studies. Lin et al quantified
ctDNA by amplifying mutations in 74 genes and showed that
ctDNA, lower than themedian value, was associated with a higher
5-year overall survival (p = 0.001) (n = 191) (90). Möhrmann
et al assessed mutations in BRAF, KRAS, and EGFR genes in
ctDNA of 20 advanced CRC patients and also found that lower
ctDNA corresponded with longer survival (91). These findings
were supported by a study of 37 patients that evaluated the
presence of KRAS mutations and p16 hypermethylation in all
stages of CRC and found a strong association between detection
of ctDNA, and a shorter survival and higher risk of recurrence
(92). Similarly, Wang et al concluded that detection of genetic
alterations in APC, p53, and KRAS in a sample of 104 pre-
operative CRC patients was linked to increased incidence of
recurrence and metastases (93).
Many studies have assessed ctDNA prior to and after
CRC resection and determined its clinical utility in detecting
recurrence. Ryan et al (n = 78) contradicted some of the studies
above with their finding that pre-operative KRAS2 mutations
in ctDNA was not an independent prognostic factor for disease
recurrence. However, they did find that KRAS2 ctDNA was
positive in patients after surgery and preceding recurrence, which
occurred a median of 4 months before CEA elevations (94).
Reinert et al had a similar finding with detection of somatic
structure variants in post-operative ctDNA an average of 10
months before recurrence in 6 out 9 CRC patients of all stages
(95). Several different studies quantified the level of ctDNA from
a panel of commonly mutated genes to assess prognosis. In
a small study of 18 patients Diehl et al found that detection
of high levels of ctDNA post-operatively was associated with
recurrence, and ctDNA was a better biomarker than CEA
(p = 0.03) (47). Schøler et al compared post-operative ctDNA
with radiological evidence of recurrence in 14/45 patients in
the study who relapsed and found that ctDNA was detected
an average of 9.4 months before CT scans (85). Kidess et al
assessed 38 patients undergoing liver metastectomy along with
CRC resection and found that post-operative ctDNA levels
anticipated recurrence earlier than conventional tools—CEA
and radiological imaging (96). Pre- and post-operative ctDNA
levels have also been evaluated for clinical utility in determining
survival. Shin et al assessed KRAS mutations in 62 stage III/IV
CRC patients undergoing surgery and found a higher rate of
ctDNA mutation detection in patients with metastases, and that
detectable ctDNA KRAS mutations correlated with a shorter
overall survival (p= 0.03) (97).
Several studies have assessed recurrence in CRC patients based
on selection of ctDNAmutations following primary tumor tissue
analysis, including a study by Ng et al (n= 44) who found certain
patients were positive pre-operatively, negative post-operatively
and then positive again prior to recurrence before any clinical
or radiological evidence (85). Tie et al found that post-operative
ctDNA was predictive of recurrence in both locally advanced
rectal cancer patients (n = 159) (98) and in stage II CRC
(p = 0.001) (n = 178) (99). These findings were irrespective of
adjuvant therapy.
Research has also been conducted on patients undergoing
chemotherapy. Studies evaluated pre-therapy ctDNA and
longitudinal ctDNA collection during treatment and its
prognostic role in predicating survival. In 97 metastatic CRC
patients, it was shown that high level of cfDNA and high
mutation loads of KRAS exon2, BRAF V600E in pre-therapy
ctDNA was associated with shorter overall survival (100). Similar
results were also obtained by Spindler et al, detection of KRAS
mutation in ctDNA correlated with shorter overall survival and
progression free survival (p = 0.001; p = 0.002) in a sample of
140 patients with chemotherapy resistant metastatic CRC (101).
Janku and colleagues longitudinally assessed advanced CRC
patients receiving chemotherapy in four different studies. In 62
patients receiving BRAF/MEK inhibitors, detection of a high
percentage of BRAF V600 ctDNA was associated with shorter
overall survival and time to failure (p = 0.005; p = 0.045) (102).
In another study of 71 patients, detection of>6.2%KRASG12/13
ctDNA was correlated with shorter survival (p = 0.001) (103).
Additionally, in a similar study with a cohort of advanced cancer
patients (68 colorectal and 3 gastroesophageal), detection of>1%
KRAS, EGFR, BRAF, or PIK3CA mutant ctDNA was associated
with a shorter median survival (104). They also tested detection
of 61 cancer related genes in 14 CRC patients and found that
patients with low variant allele frequency survived longer and the
time to treatment failure was also longer (p = 0.018; p = 0.03).
Another important finding in this study was that the allele
frequency in patients receiving systemic therapy changed in
synchronization with radiological response (p= 0.02) (105).
A few studies also looked specifically at using ctDNA as a tool
for treatment monitoring and assessing prognosis of metastatic
CRC. In a study of 211 patients, Spindler et al found that patients
with KRAS mutations in pre-therapy ctDNA, did not respond to
second-line irinotecan treatment and had shorter overall survival
and progression free survival (p = 0.04; p < 0.0001; p = 0.01)
(106). In another study of 140 patients, Spindler et al found that
pre-therapy DNA levels strongly correlated with KRAS ctDNA
levels and this was associated with poor disease control using
third-line treatment with cetuximab and irinotecan (p = 0.009)
(107). Tie et al assessed mutations in primary tumor present in
ctDNA in 53 patients and found that the changes in level of
mutant DNA correlated with radiological response to first-line
chemotherapy treatment andmajor reductions in ctDNA seemed
to be associated with a trend for increased progression free and
overall survival (108).
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DNA Methylation
Methylation changes of certain genes has been investigated by
many studies to determine prognosis in different patient groups
undergoing surgical resection and/or chemotherapy. There is
interest in whether methylated ctDNA markers parallel those
using mutations, and one study showed a significant correlation
between the two, with both being detectable prior to clinical
signs of recurrence (109). Liu et al (n = 165) found a significant
association between pre-operative ctDNA methylation of SST
and MAL and cancer specific deaths. Methylation of SST also
correlated with tumor recurrence (31).
Several studies have shown prognostic value of methylated
DNA markers. Matthaios et al (n = 155) found an association
between methylation of APC and RASSF1A in pre-operative
ctDNA and poor survival in early and advanced CRC patients
(110). A study of 397 CRC patients under surveillance,
assessed accuracy of a panel of methylated ctDNA biomarkers
(BCAT1 and IKZF1) and found that sensitivity and specificity
for recurrence was 68 and 87% respectively, significantly
higher than sensitivity of CEA (32%) with no significant
difference in specificity (94%) (37). While most studies have
assessed hypermethylation, one study (n = 95) found that
hypomethylation of CBS promoter induced by folate deficiency
was also linked to recurrence and cancer-related death (111).
Several studies have investigated the prognostic value of
DNA methylation for metastatic CRC patients and/or following
adjuvant chemotherapy. Prior to therapy, two studies (n = 467
and n = 82) showed that detection of methylated HPP1, WIF1,
and NPY in blood have been shown to be associated with poor
overall survival (112, 113). The second study showed that a
decrease in ctDNA during chemotherapy was associated with
longer median progression-free survival and overall survival
(p < 0.001; p < 0.001) (113). Methylation of 30 gene promoter
regions was assessed by Rasmussen et al in 193 patients prior
to receiving chemotherapy, and a higher number of methylated
regions was correlated with an increased risk ofmetastases.RARB
and RASSF1A methylation was associated with more aggressive
disease indicating poor survival (114). In two separate studies
Philipp et al (n = 311 and n = 259) showed that methylation of
HLTF or HPP1 was associated with larger and more advanced
CRC stage, shorter overall survival and metastases (115, 116).
Summary
There have been a larger number of studies performed in
CRC patients with survival as the key outcome compared to
recurrence (Table 5). Recurrence in cases with early stage CRC
is a particular challenge for finding prognostic markers that
justify individualized therapy aimed at reducing the chance of
recurrence. The majority of studies searching for prognostic
ctDNA biomarkers for CRC focussed on DNA mutations, with
the use of blood biomarkers that have been personalized from
primary tumor tissue analysis, showing promising sensitivity.
Such biomarkers are most effective though when based on
known mutations in surgically resected cancer. Methylated DNA
biomarkers are better suited for pre-operative prognostication
and hence have been the subject of more studies of this type,
with pre-operative detection of methylated SST showing promise
for independent prediction of recurrence, and methylated SST,
RASSF1A, and RARB being independent predictors of overall
survival. More studies are warranted in this field.
DISCUSSION
Following cancer diagnosis, clinical decisions regarding
treatment and surveillance frequency are largely driven by
pathological stage. Despite this there are a considerable
proportion of patients who still have cancer recurrence and
poor survival. Non-invasive biomarkers that can provide an
accurate prognosis assessment independent of stage are therefore
warranted. While there have been a large number of studies
conducted in gastrointestinal cancers, the majority have assessed
prognosis for CRC. Very few studies report diagnostic accuracy
for either recurrence or death (sensitivity and specificity), and
many are limited by small numbers of patients with endpoints
of recurrence or mortality. In addition, out of all of the studies
reviewed (when limiting analysis to those studies with at least 20
events of interest), very few ctDNA biomarkers are independent
predictors of recurrence or survival. For oesophageal cancer and
GIST there were no independent biomarkers for prognosis. For
gastric cancer methylated SOX17 and APC were independent
predictors of survival, with an adjusted HR of 3.0 (95% CI
1.2–7.8) (72) and 4.6 (95% CI 1.1–20.3) (71) respectively. For
CRC there were a number of ctDNA biomarkers that were
independent predictors of prognosis including DNA levels
and fragments, tumor-specific DNA mutations and DNA
methylation. A personalized ctDNA panel based on tumor tissue
analysis gave the greatest independent prediction of recurrence
with a HR of 28 (95% CI 11–68) (99). Other independent
predictors for recurrence included methylated SST (HR 2.60,
95% CI 1.37–4.94) (31) and hypomethylated CBS (HR 1.54, 95%
CI 1.18–3.02) (111). For independent prediction of survival,
seven potential biomarkers (all analyzed in pre-operative blood
samples) were found: Alu83 (HR 2.71, 95% CI 1.22–6.02)
(84), Alu244 (HR 2.70, 95% CI 1.25–5.84) (84), DNA copy
number (HR 2.61, 95% CI 1.31–5.19) (90), methylated SST
(HR 1.96, 95% CI 1.06–3.62) (31), methylated RARB (HR
1.99, 95% CI 1.07–3.72) (114), methylated RASSF1A (HR 3.35,
95% CI 1.76–6.38) (114), and hypomethylated CBS (HR 1.35,
95% CI 1.09–2.41) (111). As can be seen, in most cases the
reported hazard ratios for prognosis were not stronger than
those found with the clinicopathological variables reported in
Table 1.
Limitations in Studies of ctDNA
In this review we have not taken into consideration the
methodological differences between studies which can affect
results, leading to false positives or negatives. Variations in blood
collection tubes, storage times, and temperatures, DNA isolation
methods, and nature of analysis (automated or manual) are all
relevant to assessing benefit. One study that compared different
blood collection tubes for analysis of epigenetic alterations in
ctDNA found that some could only be stored cold for 24 h,
while others could be stored at room temperature for 48 h
(119). In addition, the use of plasma or serum can introduce
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differences in results. Serum typically has higher yields of DNA
(85, 120), but this may be from contamination of the sample
with DNA from white blood cells, which lyse during serum
processing (120). A study showed that DNA levels from serum
and plasma did not correlate. Serum DNA was associated with
the presence of liver metastases, while only DNA from plasma
was predictive for recurrences (121). Another study showed that
serum samples compared to plasma samples had a decreased
KRAS allele frequency (122). This suggests that plasma is the
optimal specimen type for analysis of ctDNA (123), but despite
this, approximately one-third of the studies that we reviewed
had used serum (20% of CRC studies, 29% of oesophageal
cancer studies, 62% of gastric cancer studies, and 100% of GIST
studies).
Other features that need to be considered for ctDNA studies
are amplicon lengths and time of collection. As circulating DNA
is highly fragmented, targeted regions of the DNA need to
account for this. By using a short amplicon assay, KRAS mutated
DNAwas detected in significantly more blood samples compared
to using a long amplicon assays (124). Time of blood collection
may also influence levels of ctDNA, as it has been shown that
total DNA and levels of methylated Septin 9 (SEPT9) have diurnal
variations (125). In patients with CRC, highest concentrations
were measured at midnight (125).
All studies, whether of mutations or methylation markers, are
subject to the chance that detection of biomarkers might not be
associated with the tumor of interest. This was supported by a
study of TAC1 hypermethylation in oesophageal cancer which
found that ∼13% of their cohort had the biomarker present in
plasma but not in the matched tumor tissue (61). They proposed
that this could indicate a risk for developing malignant disease in
the future; that it could be derived from a pre-cancerous lesion;
or it could be derived from a cancer elsewhere in the body. It is
possible that ctDNA biomarkers may not be specific to just one
cancer.While hypermethylation of the promoter region of SEPT9
shows promise for screening andmonitoring of CRC, methylated
Sept9 was also detected in 44.3% of lung cancer patients (126).
In the current review, the lack of specificity for one cancer was
seen for methylated APC and RASSF1A that have prognostic
potential in both gastric (70, 71) and colorectal cancers (110, 114).
These studies highlight the importance of optimization of ctDNA
assays.
Choice of Biomarker
Many of the studies of prognosis have used DNA mutations
as ctDNA biomarkers. Due to tumor heterogeneity, assessment
of mutations is not easily implemented in practice, with the
common genes (KRAS, BRAF, APC, TP53) mutated in only
15–40% of CRC (127). This is why several of the studies
that we reviewed applied tumor tissue analysis to personalize
ctDNA biomarkers. Extensive analysis of tumor prior to blood
may reduce cost effectiveness of the liquid biopsy, and in
addition, this limits the ctDNA biomarkers to assessment of
certain tumor subtypes rather than being a universal marker
of prognosis. Measurement of DNA methylation may be an
easier test to apply. Methylated DNA is present in a higher
proportion of tumors than mutations, for example 82% of
primary tumor tissue displays SEPT9 promoter methylation
(128). There is also evidence that aberrant methylation
is more common and frequently precedes the mutational
changes (53). The consequences of promoter methylation can
include transcriptional silencing which might facilitate tumor
progression by allowing the accumulation of additional genetic
and/or epigenetic changes (129). As the metastatic capacity of a
cell is determined at an early stage of tumor progression (130)
it seems possible to identify epigenetic biomarkers that point to
tumor aggressiveness.
Other Clinical Management Strategies for
CtDNA
Besides its use for prognosis, there is a lot of interest in the use
of ctDNA in relation to treatment strategies. As ctDNA provides
real-time results that reflect the current molecular profile of the
tumor tissue which are likely to be more representative of the
entire tumor rather than a single biopsy (131), ctDNA results
could be used to plan appropriate therapy. Analysis of ctDNA
from patients with gastrointestinal malignancies showed that
most of the patients tested had one ormore alterations potentially
actionable by experimental or approved drugs (132). ctDNA can
also be used in monitoring treatment efficacy with one such
example shown with changes of ctDNA HER2 copy number
with trastuzumab treatment in gastric cancer (133). In relation
to monitoring efficacy, ctDNA also shows value in detecting
the development of secondary resistance to therapy. Examples
have been shown in both CRC and gastric cancer with ctDNA
detecting growth of mutated clones. For example, in patients with
metastatic CRC, RAS mutations emerged during therapy with
anti-EGFR mAB which indicated resistance (134). Similarly use
of serial ctDNA measurements have shown emerging resistance
to crizotinib use in gastric cancer (135). It is also possible that
the detection of new mutations with ctDNA, or detection of
a number of biomarkers identifies tumor heterogeneity, and
indicates prognosis as well as guiding therapy. Clinical use
of ctDNA for monitoring of therapies will allow the use of
ineffective therapies to be ceased earlier. The use of ctDNA
for metastatic CRC is supported by physicians, with 69% of
physicians reporting that it was more convenient than tissue
testing, 59% believing ctDNA to be the superior method to guide
experimental therapy choice, and reporting that 89% of their
patients were satisfied with the ability of this method to improve
quality of care (136).
CONCLUSION
Application of new strategies for prognostication and
personalized management are needed to improve survival
from gastrointestinal cancers. This can be achieved with
ctDNA. Due to heterogeneity of disease, single biomarkers
are less likely to have sufficient sensitivity and specificity and
therefore a combination of biomarkers and techniques could
maximize diagnostic accuracy. Our review shows that the use
of ctDNA shows great promise as prognostic biomarkers for
recurrence and survival, however caution should be taken
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with interpreting results from studies with limited sample
sizes. As well as prognostication, markers might allow early
detection of recurrence. This will result in survival benefits from
resection when lesions are treatable, as well as permitting earlier
commencement of therapy.
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